13431-10-2Relevant articles and documents
The Reaction of Imidazolidine-2-thione with Carbon Disulphide
Yokoyama, Masataka,Motozawa, Kosei,Kawamura, Ei-ichi,Imamoto, Tsuneo
, p. 2499 - 2503 (1981)
The reaction of imidazolidine-2-thione (ethylenethiourea) with carbon disulphide in the presence of strong bases was investigated.The use of sodium hydride as base afforded 1,2-bis-ethane (6) and 2,3,6,7-tetrahydrodi-imidazothiadiazine-5-thione (8).On the other hand, reaction using n-butyl-lithium, followed by methylation, gave a dimethylated compound, methyl 2-methylthio-4,5-dihydroimidazole-1-carbodithioate (11).
Synthesis, spectroscopic characterization and in vitro anticancer activity of new platinum(II) complexes with some thione ligands?in the presence of triethylphosphine
Jomaa, Mohammed Yagoub,Altaf, Muhammed,Ahmad, Saeed,Bhatia, Gaurav,Singh, Jatinder,Altuwaijri, Saleh,Isab, Anvarhusein A.
, p. 787 - 795 (2017)
Seven new platinum(II) complexes (1–7) of triethylphosphine (Et3P) and thiones (L) with general formula, cis-[Pt(Et3P)2(L)2]Cl2 were prepared and characterized by elemental analysis, FTIR and NMR (1H, 13C & 31P) measurements. The analytical and spectroscopic data suggested the formation of the desired complexes. The complexes were tested for in vitro cytotoxicity against four cell lines: Hela (human cervical adenocarcinoma), MCF-7 (human breast carcinoma), A549 (human lung carcinoma), and HTC15 (human colon carcinoma). The anticancer activity values of compounds 1–6 are much better than cisplatin and carboplatin as indicated by their IC50 values.
Tetrakis(thione)platinum(II) complexes: Synthesis, spectroscopic characterization, crystal structures, and in vitro cytotoxicity
Mustafa, A. Zainelabdeen A.,Monim-ul-Mehboob,Jomaa,Altaf,Fettouhi,Isab,Wazeer,Stoeckli-Evans,Bhatia,Dhuna
, p. 3511 - 3524 (2015)
A new series of platinum(II) complexes based on thione ligands with general formula [Pt(thione)4]X2 (X- = Cl-, NO3-) has been synthesized and characterized using CHNS elemental analysis, infrared, 1H and 13C solution-state NMR as well as 13C and 15N solid-state NMR spectroscopy, and X-ray crystallography. The spectroscopic methods confirm the coordination of Pt(II) with thiocarbonyl groups via sulfur of the thione ligands. The X-ray structures showed a distorted square planar geometry for 1, [Pt(MeImt)4]Cl2 (MeImt = N-Methylimidazolidine-2-thione) while the hydrogen bonding interactions in 7, [Pt(iPrImt)4](NO3)2·0.6(H2O) induce a bent see-saw distortion relative to the ideal square planar geometry. The in vitro cytotoxicity studies showed that 2, [Pt(EtImt)4]Cl2 is generally the most effective, a two-fold better cytotoxic agent than cisplatin and carboplatin against MCF7 (human breast cancer).
Synthesis, Spectroscopy, and Structures of Mono- and Dinuclear Copper(I) Halide Complexes with 1,3-Imidazolidine-2-thiones
Walia, Simran,Kaur, Supreet,Kaur, Jaspreet,Sandhu, Amanpreet K.,Lobana, Tarlok S.,Hundal, Geeta,Jasinski, Jerry P.
, p. 1728 - 1736 (2015)
Copper(I) halides with triphenyl phosphine and imidaozlidine-2-thiones (L-NMe, L-NEt, and L-NPh) in acetonitrile/methanol (or dichloromethane) yielded copper(I) mixed-ligand complexes: mononuclear, namely, [CuCl(κ1-S-L-NMe)(PPh3)2] (1), [CuBr(κ1-S-L-NMe)(PPh3)2] (2), [CuBr(κ1-S-L-NEt)(PPh3)2] (5), [CuI(κ1-S-L-NEt)(PPh3)2] (6), [CuCl(κ1-S-L-NPh)(PPh3)2] (7), and [CuBr(κ1-S-L-NPh)(PPh3)2] (8), and dinuclear, [Cu2(κ1-I)2(μ-S-L-NMe)2(PPh3)2] (3) and [Cu2(μ-Cl)2(κ1-S-L-NEt)2(PPh3)2] (4). All complexes were characterized with analytical data, IR and NMR spectroscopy, and X-ray crystallography. Complexes 2-4, 7, and 8 each formed crystals in the triclinic system with Pβar{1}$ space group, whereas complexes 1, 5, and 6 crystallized in the monoclinic crystal system with space groups P21/c, C2/c, and P21/n, respectively. Complex 2 has shown two independent molecules, [(CuBr(κ1-S-L-NMe)(PPh3)2] and [CuBr(PPh3)2] in the unit cell. For X = Cl, the thio-ligand bonded to metal as terminal in complex 4, whereas for X = I it is sulfur-bridged in complex 3.
Precursor reaction kinetics control compositional grading and size of CdSe1-: XSx nanocrystal heterostructures
Hamachi, Leslie S.,Yang, Haoran,Jen-La Plante, Ilan,Saenz, Natalie,Qian, Kevin,Campos, Michael P.,Cleveland, Gregory T.,Rreza, Iva,Oza, Aisha,Walravens, Willem,Chan, Emory M.,Hens, Zeger,Crowther, Andrew C.,Owen, Jonathan S.
, p. 6539 - 6552 (2019/07/10)
We report a method to control the composition and microstructure of CdSe1-xSx nanocrystals by the simultaneous injection of sulfide and selenide precursors into a solution of cadmium oleate and oleic acid at 240 °C. Pairs of substituted thio- and selenoureas were selected from a library of compounds with conversion reaction reactivity exponents (kE) spanning 1.3 × 10-5 s-1 to 2.0 × 10-1 s-1. Depending on the relative reactivity (kSe/kS), core/shell and alloyed architectures were obtained. Growth of a thick outer CdS shell using a syringe pump method provides gram quantities of brightly photoluminescent quantum dots (PLQY = 67 to 90%) in a single reaction vessel. Kinetics simulations predict that relative precursor reactivity ratios of less than 10 result in alloyed compositions, while larger reactivity differences lead to abrupt interfaces. CdSe1-xSx alloys (kSe/kS = 2.4) display two longitudinal optical phonon modes with composition dependent frequencies characteristic of the alloy microstructure. When one precursor is more reactive than the other, its conversion reactivity and mole fraction control the number of nuclei, the final nanocrystal size at full conversion, and the elemental composition. The utility of controlled reactivity for adjusting alloy microstructure is discussed.
Platinum(II) complexes with thione ligands and methods thereof
-
Page/Page column 20, (2016/11/21)
Platinum(II) complexes having thione-based heterocyclic ligands as anticancer agents. The central platinum atom is coordinated by four of the ligands, each having a five-, six- or seven-membered heterocyclic ring with two nitrogen atoms at positions 1 and 3 of the ring and a thiocarbonyl group at position 2. Pharmaceutical compositions incorporated the platinum(II) complexes, methods of synthesizing the complexes and methods of treating cancers with the complexes or pharmaceutical compositions thereof are also described.
